New Analysis Reveals Key Drugs Linked to Ketoacidosis Risk
Background
Ketoacidosis is a serious metabolic complication characterized by high levels of ketones in the blood, often associated with diabetes mellitus. While diabetic ketoacidosis (DKA) is well-known, certain medications can also induce or exacerbate this condition, leading to drug-associated ketoacidosis (DAKA). Understanding which drugs pose the highest risk is crucial for patient safety and clinical management. This study addresses the lack of a comprehensive, large-scale analysis identifying specific drug classes with a disproportionately high association with ketoacidosis reports.
Results
The analysis identified several drug classes with significantly elevated reporting odds ratios for ketoacidosis. Sodium-glucose cotransporter 2 (SGLT2) inhibitors showed the strongest association, with an ROR of 12.5 (95% CI: 11.8-13.2), indicating a 12.5-fold higher reporting rate for ketoacidosis compared to other drugs. Among 15,487 unique reports of drug-associated ketoacidosis, 35% were linked to SGLT2 inhibitors. Atypical antipsychotics also demonstrated a significant association, with an ROR of 3.2 (95% CI: 2.9-3.5). >The study found that SGLT2 inhibitors were overwhelmingly the most frequently reported drug class associated with ketoacidosis, accounting for over a third of all DAKA reports in the FAERS database. Other drugs, including certain corticosteroids and GLP-1 receptor agonists, showed elevated RORs of 2.1 and 1.8, respectively, though with lower overall report counts.
Why It Matters
This study provides critical insights into the pharmacovigilance of drug-associated ketoacidosis, highlighting specific drug classes that warrant increased clinical vigilance. The strong signal for SGLT2 inhibitors reinforces existing warnings and underscores the need for careful patient selection and monitoring, particularly in individuals with risk factors for DKA. These findings could directly inform updated prescribing guidelines and patient education strategies, potentially leading to improved patient outcomes and reduced incidence of severe adverse events. Future research should focus on prospective studies to confirm these associations and explore underlying mechanisms, potentially leading to more targeted risk mitigation strategies.